Exegenesis Licenses AAV Capsid for Duchenne Therapy Push
HORSHAM, PA — Exegenesis Bio will supply its muscle-targeting AAV delivery technology to Modalis Therapeutics Corp. (TOKYO: 4883) under a research and licensing agreement aimed at advancing an experimental Duchenne …
Exegenesis Licenses AAV Capsid for Duchenne Therapy Push Read More